Novartis Pharms. Corp. v. Accord Healthcare, Inc., Appeal No. 2021-1070 (Fed. Cir. June 21, 2022) In this week’s Case of the Week, the Federal Circuit granted panel rehearing of and vacated its prior decision in Novartis Pharms. Corp. v. Accord Healthcare, Inc., 21 F.4th 1362 (Fed. Cir. 2022). Our write-up of that opinion can be found here. Previously, the Court had affirmed the district court’s decision that Novartis’s patent claims directed to sclerosis treatments were supported by adequate written description, and its subsequent bench trial ruling that the claims were infringed by petitioners HEC Pharm Co., Ltd. and HEC Pharm USA Inc. (HEC)...
Latest Federal Court Cases, 6/27/22
Schwabe, Williamson & Wyatt, June 2022
